Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
This trial is active, not recruiting.
|Conditions||liver cirrhosis, portal hypertension|
|Sponsor||Hvidovre University Hospital|
|Start date||August 2006|
|End date||July 2008|
|Trial size||22 participants|
|Trial identifier||NCT00332904, CD-0606-HH-UH-DK|
The study´s purpose is to investigate the effect of beta blockade or aldosterone antagonist therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients with liver cirrhosis.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Endpoint classification||pharmacokinetics/dynamics study|
|Intervention model||parallel assignment|
effect of treatment on hemodynamic and cardiac parameters
time frame: 3 weeks
Male or female participants from 18 years up to 75 years old.
Inclusion Criteria: - Liver cirrhosis - Clinical indication for treatment with betablocker or aldosterone antagonist - Must not have been treated earlier with betablocker or aldosterone antagonist - Must have been alcohol abstinent for more than 4 weeks Exclusion Criteria: - Gastrointestinal bleeding in the last 2 weeks - Encephalopathy > grade 1 - Acute medical conditions - Malignant disease - Pregnancy
|Official title||Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems|
|Description||Cardio-pulmonal complications to patients with liver cirrhosis and portal hypertension determine the patients' prognosis. Most patients have hemodynamical changes in circulation with increased cardiac output and decreased systolic function in stress. Endothelial dysfunction is a parameter for bad prognosis in cardiovascular disease. The Renin-angiotensin-aldosterone-system plays an important role in natrium and volume regulation. Descriptions of changes in the peripheral circulation and oxygenation have been deficient up to now. Patients with liver cirrhosis and portal hypertension are betablockers and/or aldosterone antagonists routine treatment - effects on peripheral hemodynamics and oxygenation in relation to central hemodynamic changes are deficient.|
Call for more information